Quality measurements for the Sarcoma Registry
The Sarcoma Registry's annual report provides an overview of selected parts of sarcoma treatment in Norway. Results in the report show that there is a high degree of centralisation of sarcoma treatment to the four university hospitals that have established multidisciplinary teams for sarcoma; Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital and the University Hospital of Nord Norway.
Quality measurements for the Sarcoma Registry
The figure shows the achievement of goals for the quality indicators defined by the Academic Council. The colored circles mark the degree of goal achievement in 2022. Red circle means low grade, yellow circle moderate, and green circle high degree of goal achievement. Specified target figures (as a percentage) show the requirement for a high degree of goal attainment.
The proportion of patients with Ewing's sarcoma and osteosarcoma who have been assessed with PET is 82 per cent, which gives a moderate degree of goal attainment, although this is an increase from the previous annual report.
The proportion of bone sarcomas referred to sarcoma centres after surgery/open biopsy is well within the target set. The proportion is somewhat higher for soft tissue sarcomas in the extremities and trunk, but is still within a high degree of goal attainment nationally.
Read more about quality objectives in the Annual Report 2022 Sarcoma (Norwegain only)
Quality improvements
The Cancer Registry of Norway has had a strong focus on increasing the coverage in recent years, which has resulted in improved reporting to all quality registries. The Cancer Registry of Norway has also established its own reporting team that will work continuously to improve coverage. It is only with good coverage that the results can be used for quality improvement nationally and in hospitals.
The work of establishing good routines for reporting from the health services will be important in the future.
It is important that sick houses take greater responsibility for reporting to the Sarcoma Registry so that the register can be used for quality improvement.
The hospitals themselves must wish to receive training in reporting. This presupposes that time, funds and personnel must be allocated. Quality registry administrators have visited relevant hospitals and provided training in what they needed. This has been both guidance in the use of KREMT (the Cancer Registry of Norway's reporting service) and cancer-specific reporting forms.
